Literature DB >> 26212378

Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: A retrospective study.

Charoen Choonhakarn1, Panita Limpawattana2, Suteeraporn Chaowattanapanit1.   

Abstract

Toxic epidermal necrolysis (TEN) is an uncommon severe cutaneous adverse reaction. Although controversies remain in the pathophysiology and management of this condition, improvements in survival and morbidity have been observed over the past decade. The aim of the present study was to demonstrate the clinical profiles of TEN in Thai patients and the treatment outcome with dexamethasone pulse therapy assessed by using the Severity of Illness Score for Toxic Epidermal Necrolysis (SCORTEN). Medical records of all patients with TEN were collected retrospectively from January 2002 to December 2012. Epidemiological features, etiologies, treatments and clinical outcomes were reviewed. Of 18 patients, the female to male ratio was 1:1 and the mean age was 49.7 years. Cephalosporins (27.8%), phenytoin (16.7%), carbamazepine, sulfonamide drugs and allopurinol (11.1% each) were implicated as leading causes of TEN. Hepatitis was the most frequent complication (77.8%). Pulsed high doses of dexamethasone 1-1.5 mg/kg per day for a short period were administrated in all cases. Two of the 18 patients receiving corticosteroids (SCORTEN 5 and 6) died. The mortality rate was 11% (2/18 patients), however, no patient receiving systemic corticosteroids died if the patients had less than 4 points on SCORTEN. The clinical features of Thai patients with TEN were similar to other reports. In conclusion, in addition to withdrawal of the suspected agent and intensive supportive care, the administration of short-term dexamethasone pulse therapy, particularly during the initial phase, may be beneficial in reducing the mortality rate.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  Thai patients; cause; mortality; severe adverse drug reaction; systemic corticosteroids; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2015        PMID: 26212378     DOI: 10.1111/1346-8138.13040

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

1.  Effectiveness and Safety of Early Short-Course, Moderate- to High-Dose Glucocorticoids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Retrospective Study.

Authors:  Zhenzhen Ye; Chunting Li; Hua Zhang; Chunlei Zhang; Xueyan Lu
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-19

2.  Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs.

Authors:  Rannakoe J Lehloenya
Journal:  Front Med (Lausanne)       Date:  2022-09-12

3.  Unusual oral findings of the toxic epidermal necrolysis in an HIV-infected patient: a case report.

Authors:  Vinicius da Costa Vieira; Viviane Almeida Sarmento; Patricia Miranda Leite Ribeiro; Eduardo Martins Netto; Carlos Brites; Liliane Lins-Kusterer
Journal:  Braz J Infect Dis       Date:  2019-09-25       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.